Reports on HIV/AIDS Findings from Department of Infectious Diseases Provide New Insights (Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis).

A new report from the Department of Infectious Diseases provides insights into the effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis. The study found that a two-drug regimen of dolutegravir and lamivudine resulted in high rates of virological suppression and well-controlled tuberculosis. The study included 89 treatment-naive individuals living with HIV, with 91.67% achieving viral suppression at 48 weeks. The findings support the real-world effectiveness and low metabolic impact of this treatment, particularly for patients coinfected with tuberculosis and HIV. [Extracted from the article]